June 11, 2024Frontiers in OncologyOpen Access

Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

View Full Paper

Ask AI

Bookmark

Authors

ACAna CordeiroAC Camargo Hospital GDGeorge DurisekThe Ohio State University MBMarjorie Vieira BatistaUniversity of Maryland, Baltimore

Discussion

Member takes

Implication

Literature review reveals manageable late cytopenias and hypogammaglobulinemia in B-cell lymphoma patients, highlighting favorable long-term safety of anti-CD19 CAR T-cell therapy.

Key Points

Late complications following anti-CD19 CAR T-cell therapy include cytopenia and hypogammaglobulinemia, but these toxicities remain clinically manageable.
Severe cytopenia affects 30%–40% of patients beyond one month post-infusion, while persistent deficits past three months drop to 3%–22%.
Literature review of published clinical trials indicates that secondary myeloid neoplasm risks remain uncertain, supporting an overall favorable benefit–risk ratio.

Cite This Study

Cordeiro et al. (2024) studied this question.

synapsesocial.com/papers/68e6542bb6db6435875e30f5 https://doi.org/10.3389/fonc.2024.1404351

View Full Paper

Ask AI

Bookmark

Implication

Literature review reveals manageable late cytopenias and hypogammaglobulinemia in B-cell lymphoma patients, highlighting favorable long-term safety of anti-CD19 CAR T-cell therapy.

Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider